Register for free to
view the full innovation profile.
CollThanide seeks to revive a former postdoc project to create collagen-linked lanthanide bioconjugates, offering disruptive diagnostic imaging and targeted cancer theraphies
About
CollThanide is a disruptive project focused on developing cutting-edge collagen mimetics linked with lanthanide metals to revolutionize diagnostics and therapeutics. Originating as a postdoctoral project, the initiative employs proprietary bioconjugation techniques to create compounds that combine diagnostic imaging with therapeutic capabilities, including targeted cancer treatments using radioactive lanthanides. These compounds uniquely target collagen biomarkers, offering advancements in peptide receptor radionuclide therapies and drug discovery. With applications ranging from enhanced diagnostic tools to preclinical and clinical therapeutic agents, CollThanide aims to push the boundaries of medical innovation in the fields of radiopharmaceuticals and precision medicine.
Key Benefits
The CollThanide project offers transformative benefits by combining diagnostic and therapeutic capabilities in a single platform. Its innovative collagen-lanthanide bioconjugates enhance diagnostic imaging (MRI, SPECT and SPECT/CT) with precision targeting, improving the detection and monitoring of diseases like osteoarthritis and cancer. These compounds also enable the development of targeted radiopharmaceutical therapies, utilizing radioactive isotopes for precision cancer treatment while offering non-radioactive surrogates for preclinical research. By focusing on collagen biomarkers, the project introduces novel approaches to drug delivery and discovery, expanding the potential for personalized medicine. Additionally, its market potential and licensing opportunities promise significant advancements in both diagnostics and therapeutics.
Applications
CollThanide’s innovative collagen-lanthanide bioconjugates hold immense potential for applications in various cancers' diagnostics and therapy as well as osteoarthritis treatment. These compounds are designed to target collagen receptors, a key feature in tumor microenvironments and damaged tissues, enabling precise delivery of imaging agents for enhanced MRI diagnostics. In cancer therapy, radioactive lanthanides provide a targeted radiotherapeutic approach, minimizing damage to surrounding healthy tissues. For osteoarthritis, these bioconjugates can facilitate early detection through improved imaging of cartilage and joint degradation while offering pathways for targeted therapeutic intervention. By addressing diagnostic and therapeutic gaps in both oncology and degenerative joint diseases, CollThanide bridges critical unmet needs in personalized medicine.